MNPR-101-Zr

MNPR-101-Zr is a radiolabeled imaging agent consisting of the humanized monoclonal antibody MNPR-101 conjugated to the radioisotope zirconium-89. It is designed for positron emission tomography (PET) imaging of cancers that express the urokinase plasminogen activator receptor (uPAR), which includes a majority of triple-negative breast, colorectal, bladder, ovarian, gastric (stomach), and pancreatic cancers. The drug enables highly specific tumor targeting and visualization in PET scans by binding to uPAR on cancer cells. Developed as part of Monopar Therapeutics' radiopharmaceutical platform in collaboration with NorthStar Medical Radioisotopes, it is currently being evaluated in Phase 1 clinical trials for its ability to detect and monitor solid tumors[1][3][4][5][6].